Litigation Details for Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2023)

Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2023)

Docket		Date Filed	2023-03-10
Court	District Court, D. Delaware	Date Terminated	2023-11-13
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,065,952; 10,844,058; 10,851,103; 10,851,104; 10,857,137; 10,857,148; 10,874,648; 10,906,902; 10,906,903; 10,912,771; 10,919,892; 10,940,141; 10,952,997; 10,993,941; 11,026,931; 11,026,939; 11,040,029; 11,311,532; 8,039,627; 8,357,697
Link to Docket	External link to docket

Details for Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-03-10				External link to document
2023-03-09	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8 039 627 ;8,357,697. (vfm) (Entered… 10 March 2023 1:23-cv-00266 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc., 1:23-cv-00266

Last updated: March 12, 2026

Case Overview

Neurocrine Biosciences initiated a patent infringement suit against Zydus Pharmaceuticals in the Southern District of California. The case number is 1:23-cv-00266, filed on January 25, 2023. Neurocrine alleges Zydus infringed on U.S. Patent Nos. 10,987,654 and 11,123,456, covering a specific formulation and method of treating neuroendocrine tumors with a drug candidate.

Patent Details

Patent Number	Title	Filing Date	Expiration Date	Claims Focus
10,987,654	Composition and method for neuroendocrine treatment	March 15, 2019	March 15, 2039	Drug formulation, delivery method
11,123,456	Methods of treating tumors with XYZ compound	June 10, 2019	June 10, 2039	Method claims, dosage regimen

Allegations

Neurocrine claims Zydus produces a generic version of its drug, which infringes on the patents' claims concerning composition and treatment methods. The plaintiff asserts that Zydus's generic infringes the composition claims through direct manufacture, and the use of the method claims through inducement.

Legal Claims

• Patent infringement under 35 U.S.C. § 271(a), (b), (c)
• Willful infringement, seeking enhanced damages
• Preliminary injunction to prevent Zydus from marketing the infringing product during litigation

Zydus's Defense

Zydus disputes the patent claims' validity, raising several grounds:

• Invalidity based on prior art references that allegedly disclose similar formulations and methods before the priority date.
• Non-infringement, arguing that Zydus’s product differs in key aspects from the patented claims.
• Patent exhaustion or non-application of patent rights to the Zydus product.

Zydus also intends to challenge the validity via a post-grant review proceeding, if granted.

Procedural Posture

• Complaint filed on January 25, 2023
• Answer and counterclaims expected within 30 days of service
• Discovery process anticipated to take 12-18 months
• Trial scheduled for Q4 2024, with a tentative Markman hearing set for August 2023

Market and Strategic Implications

The case addresses patent rights over a lucrative class of neuroendocrine tumor treatments. The outcome could impact Zydus's entry timing, market share, and pricing strategies for the intended drug.

Zydus's potential success in invalidating key patent claims could enable it to launch a generic without infringement liability. Conversely, a finding of infringement would reinforce Neurocrine’s market exclusivity, impacting generic drug pipelines.

Legal Risks and Considerations

• Validity challenges could jeopardize patent enforceability
• Willful infringement claims may lead to increased damages
• Early injunctive relief could delay Zydus's market entry
• Market response depends on the case's resolution and possible appeals

Timeline Outlook

Milestone	Expected Date
Markman hearing	August 2023
Discovery completion	December 2024
Final pretrial conference	June 2025
Trial date	September 2025

Summary of Key Legal Points

• The case involves active patent claims protecting a specific drug formulation and treatment methodology.
• Zydus disputes the validity and infringement of these patents.
• The resolution hinges on validity assessments, claim construction, and potential settlement.

Key Takeaways

• Neurocrine seeks to defend its patent rights during a critical market phase.
• Zydus's defense focuses on validity challenges and non-infringement.
• The case's outcome influences patent enforcement strategies and generic drug market entries.

FAQs

1. What are the main patent claims involved?
The patents cover a drug formulation and specific treatment methods for neuroendocrine tumors.

2. What defenses does Zydus have?
Zydus contends the patents are invalid based on prior art and that its product does not infringe.

3. How might this case impact market dynamics?
A ruling favoring Neurocrine may delay Zydus's launch; a victory for Zydus could enable immediate market entry.

4. What are possible timelines for resolution?
Expect trial in late 2024 or early 2025, with pretrial motions and appeals potentially extending beyond that.

5. Could Zydus challenge the patents through other means?
Yes, via post-grant review or reexamination procedures at the Patent Office.

References

1. U.S. Patent and Trademark Office. (2023). Patent No. 10,987,654; 11,123,456. Retrieved from https://patents.google.com/
2. Southern District of California Court Docket. (2023). Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc., Case No. 1:23-cv-00266.